VYGR
Voyager Therapeutics, Inc.
$3.33
-8.01%
$201.2M
No data for this timeframe.
Vol
Market Cap$201.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders8 funds
Inst. Value$19.3M
Inst. Activity2 buys / 1 sells
Insider Activity0B / 11S
Insider Net $-$298.0K
SEC Reports9
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001640266·Prev Close $3.62
Recent Activity
May 16, 2026
SEC
Cantor Fitzgerald initiates VYGR at Overweight — PT $5.73 (+35%) amid cluster of bullish coverage
ANALYST-UPGRADE — Impact 1/10
May 13, 2026
Press
Voyager Therapeutics presented positive 3-month GLP toxicology data for VY1706, a tau-silencing gene therapy for Alzheim
Impact 6/10
May 13, 2026
fda
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
<p align="center"><em>- VY1706 IND application process on track for Q2 2026; clinical entry expected
Apr 27, 2026
Press
Voyager Therapeutics announced eight presentations at ASGCT 2026, headlined by late-breaking oral data on VY1706, a tau-
Impact 5/10
Apr 16, 2026
SEC
Leerink Partners initiates coverage on VYGR with Outperform and $15 price target, implying 279% upside from $3.96. Firm
ANALYST-UPGRADE — Impact 7/10
Apr 16, 2026
SEC
Cantor Fitzgerald initiates coverage on VYGR with an Overweight rating and $5.73 price target, implying 45% upside from
ANALYST-UPGRADE — Impact 6/10
Apr 2, 2026
Insider
Sandrock Alfred sold 11,511 shares
President and CEO @ $3.87 ($44.5K)
Apr 1, 2026
Insider
Shiferman Gregory L. sold 50,000 shares
SVP and General Counsel @ $0.00 ($0.00)
Price Targets
$14.89
+347.1% upside
Strong Buy
Current $3.33
Low $8.00
Median $12.00
High $25.00
9 analysts
$8.00
$25.00
Analyst Ratings
8Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 17, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 12, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Sep 15, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Aug 7, 2025 | Wedbush | MAINTAIN | Outperform → Outperform |
| Apr 8, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $-1.58 ▲ +12.1% | $-1.96 — $-0.71 | 22% YoY | 7 |
| Next FY | $-1.58 ▲ +8.6% | $-2.59 — $-0.53 | 1% YoY | 9 |
| Current Q | $-0.52 ▼ -5.4% | $-0.72 — $-0.40 | 9% YoY | 9 |
| Next Q | $-0.48 ▼ -2.6% | $-0.76 — $-0.26 | -3% YoY | 9 |
Latest Reports
NEUTRAL
ANALYST-UPGRADE
1/10
Cantor Fitzgerald initiates VYGR at Overweight — PT $5.73 (+35%) amid cluster of bullish coverage
May 16, 2026
BULLISH
Press
6/10
Voyager Therapeutics presented positive 3-month GLP toxicology data for VY1706, a tau-silencing gene therapy for Alzheim
May 13, 2026
MIXED
ANALYST-UPGRADE
7/10
Leerink Partners initiates coverage on VYGR with Outperform and $15 price target, implying 279% upside from $3.96. Firm
Apr 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $12.8M | — |
| MORGAN STANLEY | $2.1M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $1.2M | TRIM |
| TWO SIGMA INVESTMENTS, LP | $875.3K | ADD |
| BANK OF AMERICA CORP | $692.1K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 2, 2026 | Sandrock Alfred | SELL | $44.5K |
| Apr 1, 2026 | Shiferman Gregory | A | $0.00 |
| Feb 24, 2026 | Carter Todd | SELL | $15.7K |
| Feb 24, 2026 | Swartz Robin | SELL | $24.3K |
| Feb 24, 2026 | Sandrock Alfred | SELL | $53.8K |
8 institutional holders with $19.3M total value (4,918,146 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, RENAISSANCE. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,266,484 | $12.8M | 66.4% | — |
| 2 | MORGAN STANLEY | 544,114 | $2.1M | 11.1% | ADD +48.1% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 296,450 | $1.2M | 6.0% | TRIM -33.1% |
| 4 | TWO SIGMA INVESTMENTS, LP | 222,713 | $875.3K | 4.5% | ADD +58.3% |
| 5 | BANK OF AMERICA CORP /DE/ | 176,097 | $692.1K | 3.6% | TRIM -58.8% |
| 6 | FMR LLC | 141,737 | $557.0K | 2.9% | — |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 137,888 | $541.9K | 2.8% | NEW |
| 8 | WELLS FARGO & COMPANY/MN | 132,663 | $521.4K | 2.7% | ADD +26.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 140,715 | 222,713 | +58.3% | $875.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 427,430 | 176,097 | -58.8% | $692.1K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 104,699 | 132,663 | +26.7% | $521.4K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 576,482 | 427,430 | -25.9% | $2.0M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 392,100 | 262,450 | -33.1% | $1.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 140,715 | — | $657.1K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 59,271 | 104,699 | +76.6% | $488.9K | 2025-Q3 |
| MORGAN STANLEY | ADD | 380,485 | 563,439 | +48.1% | $1.8M | 2025-Q2 |
| UBS Group AG | ADD | 355,932 | 455,542 | +28.0% | $1.4M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 120,200 | 392,100 | +226.2% | $1.2M | 2025-Q2 |
| UBS Group AG | ADD | 199,310 | 355,932 | +78.6% | $1.2M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 32,558 | 121,209 | +272.3% | $409.7K | 2025-Q1 |
| UBS Group AG | DOUBLED | 24,263 | 199,310 | +721.5% | $1.1M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 278,667 | 139,900 | -49.8% | $793.2K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 262,036 | 32,558 | -87.6% | $184.6K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 137,477 | — | $804.2K | 2024-Q3 |
6 unique insiders with 11 transactions. Net insider value: -$298.0K ($0.00 bought, $298.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | Sandrock Alfred | President and CEO | SELL | 11,511 | $3.87 | $44.5K |
| Apr 1, 2026 | Shiferman Gregory L. | SVP and General Counsel | A | 50,000 | $0.00 | $0.00 |
| Feb 24, 2026 | Carter Todd Alfred | Chief Scientific Officer | SELL | 4,174 | $3.76 | $15.7K |
| Feb 24, 2026 | Swartz Robin | COO & CBO | SELL | 6,458 | $3.77 | $24.3K |
| Feb 24, 2026 | Sandrock Alfred | President and CEO | SELL | 14,197 | $3.79 | $53.8K |
| Feb 24, 2026 | Jorgensen Nathan D. | Chief Financial Officer | SELL | 4,668 | $3.77 | $17.6K |
| Feb 18, 2026 | Swartz Robin | COO & CBO | SELL | 3,882 | $3.44 | $13.4K |
| Feb 18, 2026 | Sandrock Alfred | President and CEO | SELL | 11,732 | $3.41 | $40.0K |
| Feb 18, 2026 | Carter Todd Alfred | Chief Scientific Officer | SELL | 3,301 | $3.44 | $11.4K |
| Feb 10, 2026 | Carter Todd Alfred | Chief Scientific Officer | SELL | 3,525 | $3.85 | $13.6K |
| Feb 10, 2026 | Sandrock Alfred | President and CEO | SELL | 12,192 | $3.78 | $46.1K |
| Feb 10, 2026 | Swartz Robin | COO & CBO | SELL | 4,569 | $3.85 | $17.6K |
| Feb 6, 2026 | Jorgensen Nathan D. | Chief Financial Officer | A | 150,500 | $0.00 | $0.00 |
| Feb 6, 2026 | Jorgensen Nathan D. | Chief Financial Officer | A | 32,250 | $0.00 | $0.00 |
| Feb 6, 2026 | Sandrock Alfred | President and CEO | A | 402,500 | $0.00 | $0.00 |
| Feb 6, 2026 | Sandrock Alfred | President and CEO | A | 86,250 | $0.00 | $0.00 |
| Feb 6, 2026 | Swartz Robin | COO & CBO | A | 210,000 | $0.00 | $0.00 |
| Feb 6, 2026 | Swartz Robin | COO & CBO | A | 45,000 | $0.00 | $0.00 |
| Feb 6, 2026 | Ferguson Toby | Chief Medical Officer | A | 210,000 | $0.00 | $0.00 |
| Feb 6, 2026 | Ferguson Toby | Chief Medical Officer | A | 45,000 | $0.00 | $0.00 |
| Feb 6, 2026 | Carter Todd Alfred | Chief Scientific Officer | A | 154,000 | $0.00 | $0.00 |
| Feb 6, 2026 | Carter Todd Alfred | Chief Scientific Officer | A | 33,000 | $0.00 | $0.00 |
9 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 3 mixed, 3 neutral. Avg impact: 4.9/10.
MIXED
ANALYST-UPGRADE
7/10
Leerink Partners initiates coverage on VYGR with Outperform and $15 price target, implying 279% upsi
Apr 16, 2026
NEUTRAL
ANALYST-UPGRADE
1/10
Cantor Fitzgerald initiates VYGR at Overweight — PT $5.73 (+35%) amid cluster of bullish coverage
May 16, 2026
MIXED
ANALYST-UPGRADE
6/10
Cantor Fitzgerald initiates coverage on VYGR with an Overweight rating and $5.73 price target, imply
Apr 16, 2026
MIXED
ANALYST-UPGRADE
6/10
Citigroup initiates coverage on VYGR with a Buy rating and $12 price target, implying 203% upside fr
Apr 16, 2026
BULLISH
8-K
5/10
Voyager Therapeutics announced FDA clearance of its IND application for VY1706, a tau silencing gene
Jun 1, 2026
NEUTRAL
PRESS-RELEASE
4/10
Voyager Therapeutics reported Q1 2026 EPS of -$0.47, beating consensus of -$0.53 by 11%, but collabo
May 7, 2026
NEUTRAL
8-K
3/10
Voyager Therapeutics CFO Nathan Jorgensen resigned to pursue a new opportunity, with no disagreement
Apr 21, 2026
BEARISH
CLUSTER
6/10
Four executive insiders at Voyager Therapeutics (VYGR) — including the CEO, COO, CFO, and Chief Scie
Feb 26, 2026
BEARISH
CLUSTER
6/10
Three top executives at Voyager Therapeutics — the CEO, CFO, and Chief Scientific Officer — collecti
Feb 26, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 17 analysts: 8 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$14.89 mean target
+347.1% upside
Strong Buy (1.00)
$8.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $3.33 |
| Target Low | $8.00 |
| Target Mean | $14.89 |
| Target Median | $12.00 |
| Target High | $25.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current FY 2026-12-31 |
$-1.58 | $-1.96 | $-0.71 | 22.3% | +12.1% | 1↑ 0↓ | $0.0B | 7.8% | 7 |
| Next FY 2027-12-31 |
$-1.58 | $-2.59 | $-0.53 | 0.5% | +8.6% | 1↑ 0↓ | $0.1B | 41.7% | 9 |
| Current Q 2026-06-30 |
$-0.52 | $-0.72 | $-0.40 | 9.0% | -5.4% | 1↑ 0↓ | $0.0B | -8.9% | 9 |
| Next Q 2026-09-30 |
$-0.48 | $-0.76 | $-0.26 | -3.2% | -2.6% | 1↑ 0↓ | $0.0B | -18.2% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.518 | |
| 7d ago | $-0.518 | |
| 30d ago | $-0.492 | -0.027 |
| 60d ago | $-0.479 | -0.040 |
| 90d ago | $-0.446 | -0.072 |
17 analyst firms have rated this stock: 2 upgrades, 6 downgrades, 10 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 17, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 12, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Sep 15, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 7, 2025 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 8, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 13, 2025 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 13, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 12, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Mar 12, 2025 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 12, 2025 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Mar 3, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 27, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 10, 2025 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Dec 2, 2024 | Citigroup | INITIATE | — | Buy |
| Nov 14, 2024 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 16, 2024 | Leerink Partners | INITIATE | — | Outperform |
| Aug 20, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 7, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Jul 31, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 15, 2024 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| May 14, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Mar 26, 2024 | Guggenheim | INITIATE | — | Buy |
| Mar 19, 2024 | HC Wainwright & Co. | INITIATE | — | Buy |
| Mar 7, 2024 | Citigroup | INITIATE | — | Buy |
| Jan 2, 2024 | Wells Fargo | UPGRADE | Equal-Weight | Overweight |
| Aug 7, 2023 | Oppenheimer | REITERATE | Outperform | Outperform |
| May 10, 2023 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 10, 2023 | Truist Securities | INITIATE | — | Buy |
| Mar 10, 2023 | Oppenheimer | INITIATE | — | Outperform |
| Nov 3, 2021 | Chardan Capital | MAINTAIN | — | Neutral |
| Oct 7, 2021 | Baird | UPGRADE | Neutral | Outperform |
| Apr 19, 2021 | Morgan Stanley | MAINTAIN | — | Equal-Weight |
| Feb 26, 2021 | Baird | DOWNGRADE | Outperform | Neutral |
| Feb 3, 2021 | Wedbush | DOWNGRADE | Outperform | Neutral |
| Feb 3, 2021 | Morgan Stanley | MAINTAIN | — | Equal-Weight |
| Feb 3, 2021 | BTIG | DOWNGRADE | Buy | Neutral |
| Nov 11, 2020 | Oppenheimer | DOWNGRADE | Outperform | Perform |
| Nov 10, 2020 | Raymond James | DOWNGRADE | Strong Buy | Outperform |
| Nov 10, 2020 | Wells Fargo | DOWNGRADE | Overweight | Equal-Weight |
| Aug 4, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Apr 15, 2020 | Morgan Stanley | MAINTAIN | — | Equal-Weight |
| Mar 30, 2020 | Nomura | MAINTAIN | — | Buy |
| Mar 19, 2020 | Benchmark | INITIATE | — | Buy |
| Mar 4, 2020 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Mar 4, 2020 | Morgan Stanley | MAINTAIN | — | Equal-Weight |
| Mar 4, 2020 | Wedbush | MAINTAIN | — | Outperform |
| Feb 6, 2020 | Oppenheimer | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 8 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
fda
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
<p align="center"><em>- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -</em></p>
May 12, 2026
earnings_calendar
VYGR Q1 2026 Earnings Scheduled — 2026-05-12
May 7, 2026
earnings
Voyager Reports First Quarter 2026 Financial and Operating Results
<p align="center"><em>- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 -</em></p>
May 4, 2026
earnings_calendar
VYGR Q1 2026 Earnings Scheduled — 2026-05-04
Apr 27, 2026
fda
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
<p align="center"><em>- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharm
Mar 10, 2026
earnings_calendar
VYGR Q4 2025 Earnings After Market Close — 2026-03-10
Mar 9, 2026
earnings
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
<p align="center"><em>- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - </em></p>
Mar 9, 2026
earnings_calendar
VYGR Q4 2025 Earnings After Market Close — 2026-03-09